prikaz prve stranice dokumenta Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
  Download
PDF 1.58 MB
Scientific paper - Review paper
Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
Frontiers in Immunology, 14 (2023); 1086006. https://doi.org/10.3389/fimmu.2023.1086006
Bojanić, Ines; Worel, Nina; Pacini, Carolina P.; Stary, Georg; Piekarska, Agnieszka; Flinn, Aisling M.; Schell, Kimberly J.; Gennery, Andrew R.; Knobler, Robert; Lacerda, João F.; Greinix, Hildegard T.; Pulanić, Dražen; Crossland, Rachel E.

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bojanić, I., Worel, N., Pacini, C. P., Stary, G., Piekarska, A., Flinn, A. M. ... Crossland, R. E. (2023). Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers. Frontiers in Immunology, 14.. doi: 10.3389/fimmu.2023.1086006

Bojanić, Ines, et al. "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers." Frontiers in Immunology, vol. 14, 2023. https://doi.org/10.3389/fimmu.2023.1086006

Bojanić, Ines, Nina Worel, Carolina P. Pacini, Georg Stary, Agnieszka Piekarska, Aisling M. Flinn, Kimberly J. Schell, et al. "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers." Frontiers in Immunology 14 (2023). https://doi.org/10.3389/fimmu.2023.1086006

Bojanić, I., et al. (2023) 'Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers', Frontiers in Immunology, 14. doi: 10.3389/fimmu.2023.1086006

Bojanić I, Worel N, Pacini CP, Stary G, Piekarska A, Flinn AM, and sur.. Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers. Frontiers in Immunology [Internet]. 2023 February 17 [cited 2024 November 23];14. doi: 10.3389/fimmu.2023.1086006

I. Bojanić, et al., "Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers", Frontiers in Immunology, vol. 14, February 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:149689. [Accessed: 23 November 2024]

Metadata
Title (english)Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
AuthorInes Bojanić
AuthorNina Worel
AuthorCarolina P. Pacini
AuthorGeorg Stary
AuthorAgnieszka Piekarska
AuthorAisling M. Flinn
AuthorKimberly J. Schell
AuthorAndrew R. Gennery
AuthorRobert Knobler
AuthorJoão F. Lacerda
AuthorHildegard T. Greinix
AuthorDražen Pulanić
AuthorRachel E. Crossland
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Haematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant haematological diseases. Despite continuous improvements in pre- and post-transplantation procedures, the applicability of allo-HSCT is limited by life-threatening complications such as graft-versus-host disease (GvHD), engraftment failure, and opportunistic infections. Extracorporeal photopheresis (ECP) is used to treat steroid resistant GvHD with significant success. However, the molecular mechanisms driving its immunomodulatory action, whilst preserving immune function, require further understanding. As ECP is safe to administer with few significant adverse effects, it has the potential for earlier use in the post-HSCT treatment of GvHD. Thus, further understanding the immunomodulatory mechanisms of ECP action may justify more timely use in clinical practice, as well as identify biomarkers for using ECP as first line or pre-emptive GvHD therapy. This review aims to discuss technical aspects and response to ECP, review ECP as an immunomodulatory treatment modality for chronic GvHD including the effect on regulatory T cells and circulating vs. tissue-resident immune cells and consider the importance of emerging biomarkers for ECP response.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleFrontiers in Immunology
Numberingvol. 14, 1086006
e-ISSN1664-3224
DOIhttps://doi.org/10.3389/fimmu.2023.1086006
URN:NBNurn:nbn:hr:105:149689
Publication2023-02-17
Document URLhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1086006/full
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-01-15 07:54:25